Upstream Bio (UPB) Net Cash Flow (2023 - 2026)

Upstream Bio's Net Cash Flow history runs 4 years deep, the most recent figure standing at -$4.9 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 98.09% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was $25.4 million, a 36.46% decrease from a year earlier, with the FY2025 full-year figure at -$224.3 million, down 174.71% from the prior year.
• Net Cash Flow declined to -$4.9 million in Q1 2026 per UPB's latest filing, from $29.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $292.9 million in Q4 2024 and bottomed at -$254.6 million in Q1 2025.
• The 4-year median for Net Cash Flow is $411500.0 (2024), against an average of $5.0 million.
• Across the five-year window, Net Cash Flow surged 1463.48% in 2024 and tumbled 4584.41% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$21.5 million in 2023, then jumped by 1463.48% to $292.9 million in 2024, then plunged by 89.96% to $29.4 million in 2025, then tumbled by 116.5% to -$4.9 million in 2026.
• Per Business Quant, the three latest UPB Net Cash Flow figures stand at -$4.9 million (Q1 2026), $29.4 million (Q4 2025), and $26.7 million (Q3 2025).